E. Pardo

Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases

Veronika Blum, Beat Müller, Silvia Höfer et al. · European Journal of Dermatology · 2018 · 48 citations

Medicine, Oncology, Pharmacology +17

A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland

Cédric Panje, Judith E. Lupatsch, Michaela Barbier et al. · Annals of Oncology · 2020 · 26 citations · Full text

Medicine, Oncology, Pharmacoeconomics +8

A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland

Michaela Barbier, E. Pardo, Cédric Panje et al. · The European Journal of Health Economics · 2021 · 20 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17